Cologuard developer plans $350 expansion in Madison


MADISON, Wis. (AP) — The Madison-based company that specializes in detecting early-stage cancers announced Thursday that it will invest $350 million to expand its work in Wisconsin.

Exact Sciences said in a statement that expanding its Madison campuses, including a new research and development center, could eventually create an additional 1,300 jobs.

The cancer screening and diagnostics company is perhaps best known for its non-invasive colorectal cancer screening test, Cologuard. The DNA stool sample test was approved by the Food and Drug Administration in 2014 and has been used more than 7 million times, according to Exact Science.

“Continued investment in our Wisconsin-based teams and facilities will accelerate the development of new cancer screening tests and ensure that we continue to provide world-class service and critical patient answers,” said Kevin Conroy, CEO of Exact Sciences.

The company said its expansion includes three categories of projects. A new research and development facility will help improve its flagship product, Cologuard, and continue work on the early detection of multiple cancers, according to the release.

A new lab will include the latest technology and automation to increase overall testing capacity and support Cologuard development.

In addition, additional warehouse space will support the production laboratory and the research and development center.

The board of directors of Wisconsin Economic Development Corp. recently authorized an increase in Exact Science’s Enterprise Zone tax credits from $9 million to $27.5 million if the company creates at least 1,300 new jobs and invests at least $350 million dollars in capital spending by 2025.

Source link


Comments are closed.